greeksoup/ stocks
Stocks / United States / LLY / Q1 FY2025

Eli Lilly & Co. Q1 FY2025 results: revenue $12.7 billion, up 45.2% on the year

Eli Lilly & Co. (LLY) reported revenue of $12.7 billion for Q1 FY2025, the quarter ended 31 March 2025, up 45.2% on the same quarter a year earlier. Net income was $2.8 billion, up 23.0% on the year, and diluted earnings per share $3.06. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2025.

Revenue$12.7 billionup 45.2%
Net income$2.8 billionup 23.0%
Diluted EPS$3.06
QuarterQ1 FY2025ended 31 March 2025

The quarter, against the one before and a year earlier

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Revenue12,72813,5338,768+45.2%
Cost of revenue2,2242,4041,674+32.9%
Gross profit10,50411,1297,094+48.1%
Gross margin82.5%82.2%80.9%
Research and development2,7343,0222,523+8.4%
Selling, general and administrative2,4692,4241,952+26.5%
Interest expense244225180+35.7%
Pre-tax income3,4565,0392,536+36.3%
Income tax697629293+137.7%
Effective tax rate20.2%12.5%11.6%
Net income2,7594,4102,243+23.0%
Net margin21.7%32.6%25.6%
Diluted EPS$3.06$4.88$2.48+23.4%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Operating cash flow1,6662,4741,166+42.8%
Capital expenditure1,5101,496986+53.0%
Free cash flow156978180-13.1%
Free cash flow margin1.2%7.2%2.0%
Depreciation and amortisation463485401+15.5%
Share-based compensation154142159-3.6%
Buybacks1,2002,0540.0n/a
Dividends paid1,3461,1681,169+15.1%
Diluted shares, weighted901m904m904m-0.4%
Shares outstanding at period end948m948m950m-0.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Total assets89,38978,71563,944+39.8%
Cash and equivalents3,0933,2682,460+25.7%
Receivables12,03711,0067,886+52.6%
Inventory9,3117,5896,102+52.6%
Goodwill5,7705,7704,940+16.8%
Total debt, as filedn/a33,644n/an/a
Long-term debt34,50029,47424,560+40.5%
Borrowings, as the company tags themn/a29,474n/an/a
Operating lease liabilitiesn/a971n/an/a
Shareholders' equity15,76514,19212,812+23.0%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue9,4999,3538,76811,30311,43913,53312,72815,55817,60119,29219,79922,974
Cost of revenue1,8601,7881,6742,1702,1712,4042,2242,4483,0083,3723,5773,268
Gross profit7,6387,5657,0949,1339,26811,12910,50413,11014,59215,92016,22219,706
Gross margin80%81%81%81%81%82%83%84%83%83%82%86%
R&D2,4092,5632,5232,7112,7343,0222,7343,3363,4663,8023,5103,819
SG&A1,8041,9251,9522,1172,1002,4242,4692,7532,7413,1322,9343,430
Interest expense125138180184193225244249180223n/an/a
Pre-tax income4272,5092,5363,5171,5885,0393,4566,7767,2328,2668,8509,247
Tax rate113%13%12%16%39%12%20%16%23%20%16%23%
Net income-57.42,1902,2432,9679704,4102,7595,6605,5826,6387,3967,095
Net margin-1%23%26%26%8%33%22%36%32%34%37%31%
Diluted EPS-$0.06$2.42$2.48$3.28$1.07$4.88$3.06$6.29$6.21$7.39$8.26$7.94
Operating cash flow2,190-3121,1661,4663,7122,4741,6663,0878,8363,2255,33310,690
Capital expenditure9701,0719861,2251,3511,4961,5101,6972,0882,5472,3262,933
Free cash flow1,219-1,3821802412,3619781561,3906,7486783,0077,757
Buybacks0.00.00.00.04462,0541,2006927081,5082,3561,601
Dividends paid1,0161,0181,1691,1721,1701,1681,3461,3471,3451,3461,5481,546
Shares outstanding949m950m950m950m949m948m948m946m945m943m942m941m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 31 March 2025, filed 1 May 2025, accession 0000059478-25-000132: the filing on EDGAR. All of Eli Lilly & Co.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install